Market Overview:
The global canagliflozin market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market is mainly attributed to the increasing prevalence of diabetes and heart disease, and the rising demand for novel treatment options. Additionally, the increasing awareness about diabetes and its associated complications is also contributing to the growth of this market. Based on type, the global canagliflozin market can be segmented into 100mg and 300mg formulations. The 300mg formulation is expected to account for a larger share of this market than the 100mg formulation during the forecast period. This segment is expected to grow at a higher CAGR than other segments during 2018-2030 owing to its greater efficacy in treating diabetes as compared with 100mg formulations.
Product Definition:
Canagliflozin is a drug used to treat type 2 diabetes. It works by causing the kidneys to remove more sugar from the blood.
100mg:
100mg is used to treat the first signs of diabetic neuropathy. It works by improving blood flow in the brain, which is essential for nerve function. Diabetic neuropathy usually occurs as a result of poor blood circulation in the extremities due to long-term diabetes and lack of physical activity. As people get older, their risk of developing diabetes increases; this factor alone can cause neuropathy in some patients.
300mg:
300mg is an angiotensin II receptor blocker used to treat high blood pressure and heart failure. It also reduces the risk of stroke and coronary artery disease. Canagliflozin is sold in generic form under various brand names such as Cardene, Corzine, Myverde, Dronten, Minastrin 24 Fe- Pillole Comprimite e Zestoretic among others.
Application Insights:
On the basis of application, the global canagliflozin market is segmented into diabetes, heart disease and others. Diabetes held the largest share in 2017 owing to increasing incidence of diabetes coupled with rising awareness about its treatment. Canagliflozin is a big success story in the treatment of type 2 diabetes as it works better than any other drug available in the market. It reduces blood sugar levels significantly without causing hypoglycemia or weight gain and improves insulin sensitivity so much that some patients are able to discontinue their insulin therapy.
The cardiovascular diseases segment is expected to grow at a significant rate during forecast period due to growing prevalence of target diseases such as hypertension and atherosclerosis coupled with rising healthcare costs associated with them globally which will boost product demand over next eight years.
Regional Analysis:
North America dominated the global canagliflozin market in 2017. The presence of key players, favorable reimbursement policies, and rising healthcare expenditure are some of the factors contributing to its largest share. In addition, increasing awareness about diabetes prevention programs is also expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to high unmet clinical needs coupled with a large patient pool in this region. Moreover, growing disposable income levels and improving lifestyle habits are also expected to contribute toward faster growth over the next eight years.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing rapidly and is expected to reach 642 million by 2040. This will create a large pool of patients who will require treatment, including canagliflozin.
- Rising awareness about the benefits of SGLT2 inhibitors: There is growing awareness among healthcare professionals and patients about the benefits of SGLT2 inhibitors, such as canagliflozin, for the treatment of type 2 diabetes mellitus. This is likely to drive increased uptake and use of these drugs in the future.
- Launch of new products: Several pharmaceutical companies are developing new products that contain canagliflozin or other SGLT2 inhibitors as an active ingredient. These products are expected to be launched in key markets in the coming years, which should help boost sales growth for this drug class overall.
Scope Of The Report
Report Attributes
Report Details
Report Title
Canagliflozin Market Research Report
By Type
100mg, 300mg
By Application
Diabetes, Heart Disease, Others
By Companies
Janssen Pharmaceuticals, Mitsubishi Tanabe Pharma, Hansoh Pharma, Hinye
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Canagliflozin Market Report Segments:
The global Canagliflozin market is segmented on the basis of:
Types
100mg, 300mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetes, Heart Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Janssen Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Hansoh Pharma
- Hinye
Highlights of The Canagliflozin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg
- 300mg
- By Application:
- Diabetes
- Heart Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Canagliflozin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Canagliflozin is a type of medication used to treat high blood pressure. It works by relaxing the blood vessels and reducing the amount of fluid that is in the bloodstream. This can help to lower your blood pressure.
Some of the major companies in the canagliflozin market are Janssen Pharmaceuticals, Mitsubishi Tanabe Pharma, Hansoh Pharma, Hinye.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Canagliflozin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Canagliflozin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Canagliflozin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Canagliflozin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Canagliflozin Market Size & Forecast, 2018-2028
4.5.1 Canagliflozin Market Size and Y-o-Y Growth
4.5.2 Canagliflozin Market Absolute $ Opportunity
Chapter 5 Global Canagliflozin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Canagliflozin Market Size Forecast by Type
5.2.1 100mg
5.2.2 300mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Canagliflozin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Canagliflozin Market Size Forecast by Applications
6.2.1 Diabetes
6.2.2 Heart Disease
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Canagliflozin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Canagliflozin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Canagliflozin Analysis and Forecast
9.1 Introduction
9.2 North America Canagliflozin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Canagliflozin Market Size Forecast by Type
9.6.1 100mg
9.6.2 300mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Canagliflozin Market Size Forecast by Applications
9.10.1 Diabetes
9.10.2 Heart Disease
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Canagliflozin Analysis and Forecast
10.1 Introduction
10.2 Europe Canagliflozin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Canagliflozin Market Size Forecast by Type
10.6.1 100mg
10.6.2 300mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Canagliflozin Market Size Forecast by Applications
10.10.1 Diabetes
10.10.2 Heart Disease
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Canagliflozin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Canagliflozin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Canagliflozin Market Size Forecast by Type
11.6.1 100mg
11.6.2 300mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Canagliflozin Market Size Forecast by Applications
11.10.1 Diabetes
11.10.2 Heart Disease
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Canagliflozin Analysis and Forecast
12.1 Introduction
12.2 Latin America Canagliflozin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Canagliflozin Market Size Forecast by Type
12.6.1 100mg
12.6.2 300mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Canagliflozin Market Size Forecast by Applications
12.10.1 Diabetes
12.10.2 Heart Disease
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Canagliflozin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Canagliflozin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Canagliflozin Market Size Forecast by Type
13.6.1 100mg
13.6.2 300mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Canagliflozin Market Size Forecast by Applications
13.10.1 Diabetes
13.10.2 Heart Disease
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Canagliflozin Market: Competitive Dashboard
14.2 Global Canagliflozin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Janssen Pharmaceuticals
14.3.2 Mitsubishi Tanabe Pharma
14.3.3 Hansoh Pharma
14.3.4 Hinye
